JingJing Pharmaceutical Co., Ltd. was established in October 2007, covering an area of 310 mu, with a registered capital of 257.28 million yuan and more than 700 employees. It is a national high-tech enterprise and a national technological innovation demonstration enterprise specializing in the research, development, production and sales of sterile APIs, Amino acids and Vitamin nutrition fortifiers.
In December 2015, it was successfully listed on the New Third Board securities market with the security code of 835033. Since its listing, it has received attention and recognition from all aspects in the capital market, introduced a number of market makers and strategic investment institutions, and entered the innovation layer in the first batch. After listing, the company has implemented three targeted additional offerings, with a total financing of 240 million yuan, mainly invested in core technology research and development, extension of the main product industry chain, project technology innovation, and replenishment of working capital, forming a number of core technical barriers, and gradually establishing the company’s leading position in the subdivided industries.